The frequency of TP53 mutations and RAS mutations was numerically greater in the NCI-MATCH cohort for each histology, as has been observed in other populations with advanced cancer.19,20 However, these alterations did not correlate with number of previous treatments (Data Supplement). Here, TP53 is linked to cancer.